It is an essential antioxidant in the placenta because it reduces oxidative stress by constantly scavenging for free radicals, i.e., maintain the placentas integrity
Compounded semaglutide uses the same active ingredient as FDA-approved products but is prepared by compounding pharmacies rather than the original manufacturer
It was first isolated from the unripe berries of the Sorbus aucuparia -rowan tree-, hence its name
K.HurnP
Factors affecting individual response: Baseline Characteristics: Starting BMI (people with higher BMI often lose more total pounds) Age (metabolism slows with age, which may affect the rate of loss) Sex (men often lose faster than women initially, due to hormonal factors) Genetics (some people are GLP-1 "super-responders," others less so) Behavioral Adherence: Calorie reduction compliance (medication reduces appetite, but you must actually eat less) Physical activity level (combining medication with exercise improves results) Sleep quality (poor sleep impairs weight loss, even on medication) Stress management (chronic stress elevates cortisol, affects fat storage) Alcohol consumption (liquid calories still count) Medical Factors: Metabolic health (insulin resistance, thyroid function, PCOS) Medications (some meds cause weight gain, counteracting GLP-1 effects) Menopause status (hormonal changes affect the weight loss rate) Previous weight loss attempts (metabolic adaptation from yo-yo dieting) Medication Factors: Dose reached (higher doses generally more effective, if tolerated) Adherence (missing injections reduces effectiveness) Side effect tolerance (if nausea prevents eating adequate protein, muscle loss occurs) Realistic Timeline (Based on General GLP-1 Patterns) The following timelines describe generalized patterns observed in clinical research and clinical practice with FDA-approved tirzepatide and are not predictive of individual results or outcomes with compounded medications
